Elsevier

Biological Psychiatry

Volume 51, Issue 4, 15 February 2002, Pages 305-311
Biological Psychiatry

Original article
High rate of autoimmune thyroiditis in bipolar disorder: lack of association with lithium exposure

https://doi.org/10.1016/S0006-3223(01)01217-3Get rights and content

Abstract

Background: We assessed the prevalence of thyroperoxidase antibodies (TPO-Abs) and thyroid failure in outpatients with bipolar disorder compared with two control groups.

Methods: The TPO-Abs of outpatients with DSM-IV bipolar disorder (n = 226), a population control group (n = 252), and psychiatric inpatients of any diagnosis (n = 3190) were measured. Thyroid failure was defined as a raised thyroid stimulating hormone level, previously diagnosed hypothyroidism, or both. Subjects were compared with attention to age, gender, and exposure to lithium.

Results: The TPO-Abs were more prevalent in bipolar patients (28%) than population and psychiatric controls (3–18%). The presence of TPO-Abs in bipolar patients was associated with thyroid failure, but not with age, gender, mood state, rapid cycling, or lithium exposure. Thyroid failure was present in 17% of bipolar patients and more prevalent in women. It was associated with lithium exposure, especially in the presence of TPO-Abs, but not with current rapid cycling, although an association may have been masked by thyroid hormone replacement.

Conclusions: Thyroid autoimmunity was highly prevalent in this sample of outpatients with bipolar disorder and not associated with lithium treatment. These variables appear to be independent risk factors for the development of hypothyroidism, especially in women with bipolar disorder.

Introduction

Abnormalities in thyroid function are more prevalent in patients with mood disorder than in the general population and may interfere with treatment responsiveness (Hendrick et al 1998). Although clinical hyper- or hypothyroidism may be present, mood disorders are more frequently associated with more subtle dysfunction of the hypothalamic-pituitary-thyroid axis (Hendrick et al 1998). In bipolar disorder, some studies Bauer et al 1990, Cho et al 1979, Cowdry et al 1983, Kusalic 1992 reported that overt or subclinical hypothyroidism was more prevalent in patients with a rapid cycling course, although others Bartalena et al 1990, Joffe et al 1988, Post et al 1997, Wehr et al 1988 did not find this association. Lithium, frequently used in bipolar disorder, has antithyroid effects that may lead to clinical or subclinical hypothyroidism in up to 23% of patients (Kleiner et al 1999). Lithium interferes with the synthesis and release of thyroid hormones through various mechanisms, and it has been suggested that it induces or exacerbates the development of autoimmune thyroiditis Hassman and McGregor 1988, Myers et al 1985, Wilson et al 1991.

Autoimmune thyroiditis is a major cause of hypothyroidism and is marked by the presence of thyroid antibodies. Asymptomatic autoimmune thyroiditis with a euthyroid state and a mildly increased level of circulating antibodies is not uncommon, occurring in 5% to 15% of the normal population, predominantly women, and increasing with age (Rapoport and McLachlan 1996). Positivity for thyroid antibodies is associated with lymphocytic infiltration of the thyroid gland (Yoshida et al 1978) and constitutes a risk factor for the development of thyroid failure (Vanderpump et al 1995). After the discovery of thyroid antibodies in 1956, they were generally assayed by indirect immunofluorescence (IIF). This test yields two varieties of thyroid antibodies: those that react with the cytoplasm of thyrocytes (anticytoplasmic antibodies) and those that react with components of the colloidal spaces in the thyroid follicles (anticolloid antibodies). It had already been established at that time that anticolloid antibodies reacted mainly with thyroglobulin (anti-Tg antibodies). The anticytoplasmic antibodies later appeared to react with components in the microsomal fraction of the thyrocytes (antimicrosomal antibodies). This variety turned out to be specific for the enzyme thyroid peroxidase (TPO; Portmann et al 1985).

Many commercially available test systems for these thyroid-reactive antibodies have been developed over time. Assays for thyroid microsomal antibodies (the IIF and hemagglutination assays) have now largely been replaced by assays measuring antibodies to purified or recombinant TPO. Although there is in general a strong correlation between the various assay systems for thyroid antibodies, thyroperoxidase antibodies (TPO-Abs) are more sensitive than microsomal antibodies (Rapoport and McLachlan 1996). Probably they are also less specific to test for lymphocytic thyroiditis. Antibodies to TPO/microsomes are considered better markers for lymphocytic thyroiditis than antibodies to Tg and are therefore preferentially or solely used (Doniach et al 1982).

Studies are inconsistent as to whether thyroid antibodies are elevated in bipolar disorder, with reported rates ranging from 0% to 43%, and whether lithium exposure is associated with the occurrence of thyroid antibodies Bartalena et al 1990, Bochetta et al 1996, Calabrese et al 1985, Haggerty et al 1987, Haggerty et al 1990, Haggerty et al 1997, Hornig et al 1999, Leroy et al 1988, Lazarus et al 1981, Lazarus et al 1986, Myers et al 1985, Rapaport 1994, Wilson et al 1991. Reasons for these discrepancies may include differences in diagnostic groups, sample size, male-female ratio, antibody assessment methodology, and medication status. Of the published studies that used control groups, some Haggerty et al 1990, Haggerty et al 1997, Wilson et al 1991, but not all Bartalena et al 1990, Hornig et al 1999, Rapaport 1994, found a higher prevalence of thyroid antibodies in bipolar disorder, especially in depressed and mixed states. One study found a positive association between the occurrence of thyroperoxidase antibodies and a history of rapid cycling (Oomen et al 1996). The presence of thyroid antibodies has also been associated with a poor response to antidepressant treatment (Prange et al 1990).

To further study thyroid autoimmunity in bipolar disorder, we evaluated TPO-Abs and serum thyroid stimulating hormone (TSH) in an international, multicenter study on a large cohort of DSM-IV bipolar outpatients and compared TPO-Ab rates in these patients with a general population control group and a psychiatric inpatient group. We additionally examined thyroid parameters according to demographic, illness, and treatment variables.

Section snippets

Methods and materials

The subjects were 226 outpatients (112 men and 114 women) with bipolar I (n = 178), II (n = 42), or not otherwise specified (NOS; n = 6) disorder, aged 23 to 83 years, from the Stanley Foundation Bipolar Network, a multicenter longitudinal treatment research program performed in the United States and the Netherlands Leverich G et al in press, Suppes et al in press. All patients gave written informed consent for the study. A DSM-IV diagnosis was made by means of the SCID-I/P Research Version

Prevalence of TPO-Abs

Table 1 displays the overall occurrence of TPO-Abs in bipolar outpatients and the two control groups, differentiated by gender and age. In the general population control group TPO-Ab prevalences ranged from 3.0% to 17.8% depending on the gender and the assay system used. As expected, there was a higher prevalence in women. In psychiatric inpatient control subjects tested with the lumi-nescent system, TPO-Ab prevalences ranged from 3.7% to 15.3% depending on gender and age and were not

Discussion

To our knowledge, this is the largest controlled sample of well-diagnosed DSM-IV bipolar patients to be assessed for thyroid autoimmunity and its relationship to thyroid failure and lithium exposure. Compared with the two control groups, we found that outpatients with bipolar disorder had a higher prevalence of TPO-Abs. It has been suggested that previously reported increased thyroid antibody titers in psychiatric patients are mainly due to inadequate control for age and gender (Hornig et al

Acknowledgements

The authors acknowledge the generous support from the Theodore and Vada Stanley Foundation. We thank H.A.P.S. Oomen, M.D., Ph.D., for the collection of the psychiatric control group; H. de Wit for the processing of the blood samples; R. Docter, Ph.D., for the FT4 testing; G.W. Akkerhuis, M.S., for assistance in preparing the manuscript; and J.J. Bartko, Ph.D., for statistical advice.

References (42)

  • M.S Bauer et al.

    Rapid cycling bipolar affective disorder. I. Association with grade I hypothyroidism

    Arch Gen Psychiatry

    (1990)
  • A Bochetta et al.

    Six-year follow-up of thyroid function during lithium treatment

    Acta Psychiatr Scand

    (1996)
  • A Bochetta et al.

    Ten-year follow-up of lithium patients with special reference to thyroid function

    Bipolar Disord

    (1999)
  • J.R Calabrese et al.

    Autoimmune thyroiditis in manic-depressive patients treated with lithium

    Am J Psychiatry

    (1985)
  • J.J Cho et al.

    The effect of lithium treatment on thyroid function in patients with primary affective disorder

    Am J Psychiatry

    (1979)
  • R.W Cowdry et al.

    Thyroid abnormalities associated with rapid cycling bipolar illness

    Arch Gen Psychiatry

    (1983)
  • D Doniach et al.

    The autoimmune endocrinopathies

  • M.B First et al.

    Structured ClinicalIinterview for DSM-IV Axis I Disorders, Patient EditionSCID-I/P (Version 2.0)

    (1996)
  • J.J Haggerty et al.

    Prevalence of antithyroid antibodies in mood disorders

    Depress Anxiety

    (1997)
  • J.J Haggerty et al.

    Relationship of serum TSH concentration and antithyroid antibodies to diagnosis and DST response in psychiatric inpatients

    Am J Psychiatry

    (1987)
  • R.W Hassman et al.

    Lithium and autoimmune thyroid disease

  • Cited by (0)

    View full text